一项前瞻性研究:评估Nuro经皮胫神经调控系统在未用药膀胱过度活动症患者中的疗效
本研究前瞻性评估Nuro经皮胫神经调控(PTNM)治疗未用药膀胱过度活动症(OAB)患者12周后急迫性尿失禁发作、排尿频率及生活质量的变化。120例受试者接受每周PTNM,第12次治疗后急迫性尿失禁每日减少2.4±2.1次、排尿频率每日减少1.7±2.5次(均P<.0001),无严重或非预期不良事件。结论认为PTNM对未用药OAB患者有效且安全。
要点
- 未用药OAB患者接受12周Nuro PTNM后急迫性尿失禁每日减少2.4±2.1次(P<.0001)。
- 基线有尿频者第12次治疗后排尿频率每日减少1.7±2.5次(P<.0001)。
- 最常见不良事件为器械部位疼痛和肢体疼痛,各3.3%(4/121),无严重或非预期不良事件。
核心结论
- 使用Nuro的PTNM对未用药OAB患者是有效且安全的治疗。
研究设计与样本
- 前瞻性研究,纳入154例受试者,其中120例符合标准并接受PTNM治疗。
- 受试者接受12次每周PTNM治疗,通过膀胱日记评估基线至12周的排尿症状变化。
- 平均年龄64.8岁,OAB诊断平均病程3.4年,女性占86%,入组前均未尝试OAB药物治疗。
主要发现
- 基线急迫性尿失禁为每日3.5±2.5次(均值±标准差),第12次治疗后较基线减少2.4±2.1次(P<.0001)。
- 基线有尿频者排尿频率为每日11.5±2.9次,第12次治疗后减少1.7±2.5次(P<.0001)。
- 96%(116/120)受试者完成研究并提供主要终点日记数据,平均完成11.6次治疗。
- 最常见不良事件为器械部位疼痛3.3%(4/121)和肢体疼痛3.3%(4/121),无严重或非预期不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate changes from baseline in urgency urinary incontinence episodes, urinary frequency and quality of life through 12 weeks of percutaneous tibial neuromodulation (PTNM) therapy using NURO in drug-naïve overactive bladder syndrome (OAB) subjects. METHODS: Eligible subjects underwent 12 weekly PTNM sessions with the NURO system. Changes in voiding symptoms were evaluated with bladder diaries from baseline through 12 weeks. Analyses were conducted for subjects with data at baseline and follow-up visits (sessions 1, 4, 8, and 12). Safety was evaluated through adverse events (AE) related to the device, procedure, and therapy. RESULTS: Of 154 subjects enrolled in the study,120 subjects met study criteria and received PTNM. The mean age was 64.8 years, mean duration of OAB diagnosis was 3.4 years and 86% female subjects. No subjects tried OAB medication prior to enrollment. At baseline, patients had 3.5 ± 2.5 (mean ± SD) UUI episodes/day. Statistically significant improvement in urgency urinary incontinence episodes from baseline was observed at each follow-up visit (P < .0001), with a reduction of 2.4 ± 2.1 episodes after session 12 from baseline. Subjects with urinary frequency at baseline had 11.5 ± 2.9 voids/day. After session 12, a statistically significant reduction of 1.7 ± 2.5 voids/day was observed (P < .0001). Ninety-six percent (116/120) of subjects completed the study with diary data for the primary objective with an average of 11.6 sessions. There were no serious or unanticipated AEs. The most common AEs were medical device site pain (3.3%, 4/121) and extremity pain (3.3%, 4/121). CONCLUSION: PTNM using NURO is an effective and safe treatment for drug-naïve patients with OAB.
引用
- Kobashi K, Nitti V, Margolis E, et al. A Prospective Study to Evaluate Efficacy Using the Nuro Percutaneous Tibial Neuromodulation System in Drug-Naïve Patients With Overactive Bladder Syndrome. Urology. 2019. PMID: 31199966. doi:10.1016/j.urology.2019.06.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。